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melatonin in hospitalized patients?Impaired consciousness ranging from somnolence to confusion,
delirium, stupor and coma has been reported in almost 15% of hos-
pitalized patients with Coronavirus Disease 2019 (COVIDe19) [1].
These disturbances might depend on a direct effect of the SARS-
CoV-2, but also on well-known precipitating factors such as pro-
longed hospitalization, pain, constipation, urinary retention and a
broad range of metabolic abnormalities that occur during the
course of a severe infection. Delirium has previously been esti-
mated to occur in up to 50% of hospitalized elderly patients and
80% of critically ill patients who receive mechanical ventilation
[2], and reported rates are likely to rise by the end of this ongoing
pandemic. Although pathogenetic mechanisms of delirium are
poorly understood, crucial contributing roles have been hypothe-
sized for neurotransmitter imbalance, proinflammatory cytokines,
tissue hypoxia and sleep deprivation.
Sleep deprivation is a modifiable risk factor but also a conse-
quence of delirium itself. Administration of Melatonin or Melatonin
Receptor Agonists (MRA) has been robustly associated with a short-
ened Intensive Care Unit (ICU) stay, reduced prevalence of delirium
and improved sleep quality [3]. Given its safety, Melatonin should
be considered a firsteline agent to address sleepewake rhythm
and consciousness disturbances to minimize administration of
molecules that can worsen delirium in the elderly or central respi-
ratory depression such as benzodiazepines or antipsychotics.
It is noteworthy that, based on its anti-inflammatory, anti-
oxidative and immune-enhancing features, a putative effect of
melatonin in alleviating infection-induced acute respiratory
distress has also been proposed [4]. In animal models, this natural
hormone has been shown to improve acute lung injury by acting as
a direct antioxidant and via melatonin receptor activation. The pro-
tective effect of Ramelteon (an MRA) against ventilatoreinduced
lung injury, has recently been shown to depend on the upregula-
tion of Interleukin (IL-10) in rats [5].
Melatonin's safety indoses up to 10mghasbeen shown to bevery
high in ICU patients and should be used in the prevention and treat-
mentof sleepdisturbances anddelirium inCOVIDe19.Although spe-
cific studies are needed, higher dosesmight also reduce the impact of
the cytokine storm that is emerging as immunopathological
pathway in a subgroup of patients with worse prognosis.
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